Simulations Plus

Collaboration will apply Turin to explore mechanistic QSP model structures at scale and bring insights to development decisions where traditional modeling timelines have limited their use

The transaction was originally announced on June 16, 2026. At the effective time of the merger each Simulations Plus shareholder received $18.50 in cash per share. As a result of the completion of the transaction, Simulations Plus has become a privately held company, and its common stock will no longer trade on the Nasdaq Global Select Market.

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, announced the expiration of the waiting period...

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its third quarter fiscal 2026, ended May 31, 2026.

New capabilities connect AI agents, scientific literature, and validated computational engines to accelerate model-informed drug development

Stockholders to Receive $18.50 Per Share in Cash Representing a 26% Premium to 60-day Volume-Weighted Average Price

Transaction to Strengthen Simulations Plus and Accelerate Growth Through Anticipated Combination with Chemical Computing Group

Simulations Plus will be participating in the 23rd Annual Craig-Hallum Institutional Investor Conference.

Combines validated scientific engines with accelerated computing and AI to enable more scalable, integrated modeling workflows across the drug development lifecycle

Mechanistic modeling approach and experimental integration designed to improve early risk identification, strengthen regulatory confidence, and expand AI-enabled workflows connecting data to decision-making

More than 1,400 participants across 65+ countries underscores accelerating adoption of model-informed workflows and growing demand for applied modeling expertise

Revenue grew 8% with increases in both software and services

Co-development initiatives to advance next-generation workflows, accelerate adoption, and expand the role of AI within model-informed drug development

Expert panel at the 2026 ASCPT Annual Meeting brings together leaders with industry and regulatory experience to explore practical, accountable AI implementation

Extended projects support ongoing research into computational approaches and new approach methodologies for food and chemical safety assessment

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in the upcoming investor conferences...

Showcases platform momentum, strategic priorities, and long-term value creation outlook

Investor Day on January 21, 2026, to present new product vision and AI solutions

Driving Growth with Integrated Software, Services, and AI-Enabled Ecosystem

Conference call to be on Thursday, January 8, 2026, at 5 p.m. ET

Validated engines and AI-orchestrated ecosystem align with the emerging regulatory framework